固定剂量率方法滴注吉西他滨治疗恶性肿瘤的临床观察  

Clinical study on gemcitabine administrated by fixed dose rate to treat malignant tumors

作　　者：练英妮[1] 李曙平[1] 欧庆连[1] 杨惠娟[1] 邵剑锋[1] 叶金辉[1] 

机构地区：[1]广东省肇庆市第一人民医院肿瘤部,526021

出　　处：《广州医药》2006年第3期49-52,共4页Guangzhou Medical Journal

摘　　要：目的探讨用“固定剂量率”方法使用吉西他滨治疗恶性肿瘤的可行性。方法23例经病理或影像学资料证实的恶性肿瘤患者(NSCLC、NPC、经治复发乳腺癌及胰腺癌)接受GP方案化疗(其中吉西他滨采用“固定剂量率”方法滴注)3周重复,每名患者至少完成两周期化疗,并评价化疗毒副作用及疗效。结果共完成51周期化疗,所有患者均可进行疗效及毒副反应评价。总有效率:52.17%;获益率(CR+PR+SD):86.95%。毒性反应主要为血液学毒性,尤其Ⅲ/Ⅳ度血小板降低占31.4%(16/51)周期。结论在GP方案中采用固定剂量率滴注吉西他滨治疗中晚期NSCLC、鼻咽癌、经治复发乳腺癌及中晚期胰腺癌是可行的方法,具有较高有效率、临床受益率及临床受益反应率,其毒副作用可耐受,值得进一步研究,以探讨合适的吉西他滨用量。Objective This study was to explore the possibility of approach to treat malignant tumors by using fixed dose rate of gemicitabine. Methods Total 32 pathologically or imaging-diagnosed patients with malignant tumors （NSCLS, NPC, relapsed breast cancer and pancreatic cancer） were enrolled. GP regimen （Gemcitabine： 1200 mg/m^2 at fixed dose rate of 10 mg/m^2 per minute; DDP： 80-100 mg/m^2） was administrated to these patients every 3 weeks. And for each patient, at least two cycles of GP was received. Both the response and side effects were observed. Results Total 51 cycles of treatments were finished and all patients were evaluable for both response and side effects to chemotherapy. The total response rate is 52.17% and benefit rate （CR ＋ PR ＋ SD） was 86.95%. The major side effect is hematological toxicity. Ⅲ/Ⅳ grade thrombocytopenia were occurred in 31.4% （16/51） of cycles. Conclusion The GP regimen with fixed dose rate of gemcitabine is feasible in the treatment of advanced NSCLC, NPC, relapsed breast cancer and advanced pancreatic cancer. This regimen is of high response rate, clinical benefit response. The side effects are tolerable. This regimen is worth of further study to explore the appropriate dosage of gemcitabine.

关 键 词：吉西他滨 固定剂量率 恶性肿瘤 

分 类 号：R730.5[医药卫生—肿瘤]